Biosimilar approvals in the U.S. are expected to increase during the next five years, but safety concerns among physicians and the need for greater regulatory clarity concerning therapeutic interchangeability could hinder market uptake, according to a new Tufts Center for the Study of Drug Development (CSDD) study.